Prognostic value of the CONUT score in newly diagnosed diffuse large B‑cell lymphoma
The Controlling Nutritional Status (CONUT) score, an immunonutritional index based on serum albumin, total cholesterol and lymphocyte count, has emerged as a potential prognostic marker in this setting.
The Controlling Nutritional Status (CONUT) score, an immunonutritional index based on serum albumin, total cholesterol and lymphocyte count, has emerged as a potential prognostic marker in this setting.
In patients with diffuse large B‑cell lymphoma, a high pre‑treatment CONUT score is associated with worse overall survival and progression‑free survival, indicating that routine nutritional assessment may improve risk stratification.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers